Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 24;15(3):371-374.
doi: 10.5306/wjco.v15.i3.371.

High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma

Budhi Singh Yadav  1
Affiliations
Editorial

High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma

Budhi Singh Yadav. World J Clin Oncol. .

Abstract

In this editorial I comment on the article, published in the current issue of the World Journal of Clinical Oncology. Primary central nervous system lymphoma (PCNSL) is a disease of elderly and immunocompromised patients. The authors reported clinical results of 19 patients with PCNSL treated with zanubrutinib/high dose methotrexate (HD-MTX) until disease progression. They demonstrated that the combination of zanubrutinib with HD-MTX led to a marked clinical response and tolerability among these patients. They also observed that cerebrospinal fluid liquid biopsy to detect circulating tumor DNA may be a good option for evaluating treatment response and tumor burden in patients with PCNSL. PCNSL is a challenging disease for treatment as these patients present with different neurological states and comorbidities. Treatment has evolved over the years from whole brain radiotherapy to HD-MTX followed by autologous stem cell transplant. Gradually, treatment of patients with PCNSL is going to become individualized.

Keywords: High dose methotrexate; Liquid biopsy; Primary central nervous system lymphoma; Whole brain radiotherapy; Zanubrutinib.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

References

    1. Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol. 2023;14:606–619. - PMC - PubMed
    1. Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017:565–577. - PMC - PubMed
    1. Radotra BD, Parkhi M, Chatterjee D, Yadav BS, Ballari NR, Prakash G, Gupta SK. Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India. Surg Neurol Int. 2020;11:424. - PMC - PubMed
    1. Makhdoomi R, Nayil K, Rayees A, Kirmani A, Ramzan A, Khalil MB, Dhar A, Besina S, Chanda N, Lone AR, Qadiri S, Maqbool M. Primary CNS lymphoma in immunocompetent: a review of literature and our experience from Kashmir. Turk Neurosurg. 2011;21:39–47. - PubMed
    1. Beraldo GL, Brito ABC, Delamain MT, Souza CA, Lima CSP, Bonfitto JFL, Queiroz LS, Reis F. Primary infratentorial diffuse large b-cell lymphoma: a challenging diagnosis in an immunocompetent patient. Rev Assoc Med Bras (1992) 2019;65:136–140. - PubMed

Publication types